NSE filing, NSE: SHALBY. Summary written from the filing by ALFA Finder's alert engine.
Shalby Ltd: key numbers
- Share price
- ₹121.30
- Market cap
- ₹1,310 Cr
- Revenue (annual)
- ₹1,141 Cr
- Net profit (annual)
- ₹37.39 Cr
- P/E (TTM)
- 33.3×Sector 51.1×
- Promoter holding
- 74.33%+0.00% QoQ
- FII holding
- 4.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shalby Ltd
All →Shalby Board Meeting Date
Shalby Limited has scheduled a board meeting for November 3, 2026, to consider and approve the unaudited financial results for the quarter ended September 30, 2026.
Shalby Other Announcement
Shalby Ltd filed its quarterly shareholding pattern as of September 30, 2026, disclosing the promoter and public shareholding structure in compliance with SEBI regulations.
Shalby Adverse Business Impact
Shalby Limited's Jabalpur unit faces a registration suspension by local authorities following a minor fire. The company expects no material financial impact from this event.
Shalby Management Change
Shareholders at the AGM did not approve the appointment of Mr. Shanay Vikram Shah as Director, resulting in his cessation from the Board effective September 10, 2026.
Shalby Annual General Meeting
Shalby Limited held its 22nd Annual General Meeting on September 10, 2026. The meeting covered adoption of financial statements and appointment of a whole-time director.
Shalby Other Announcement
Shalby Limited has issued a letter to shareholders providing the web-link for the Annual Report for FY 2025-26. The 22nd Annual General Meeting is scheduled for September 10, 2026.
Other regulatory approval announcements
All →Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
KFIN Technologies Regulatory Approval
KFin Technologies' Thai subsidiary received a Foreign Business License from Thailand's Ministry of Commerce. The license enables the subsidiary to conduct permitted business activities under local law.